Morgan Stanley initiated coverage on shares of CervoMed (NASDAQ:CRVO – Free Report) in a research note released on Friday morning, Marketbeat reports. The brokerage issued an overweight rating and a $35.00 price objective on the stock.
Other research analysts have also recently issued reports about the company. Canaccord Genuity Group reissued a buy rating and issued a $65.00 price target on shares of CervoMed in a report on Thursday, July 25th. Brookline Capital Management assumed coverage on shares of CervoMed in a report on Monday, July 8th. They issued a buy rating and a $63.00 target price on the stock.
View Our Latest Analysis on CRVO
CervoMed Stock Performance
CervoMed (NASDAQ:CRVO – Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.05. The business had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $2.00 million. Equities research analysts predict that CervoMed will post -1.44 EPS for the current fiscal year.
Institutional Investors Weigh In On CervoMed
A number of hedge funds have recently made changes to their positions in CRVO. Bank of New York Mellon Corp bought a new stake in CervoMed in the second quarter worth $236,000. CWM LLC purchased a new position in shares of CervoMed in the 4th quarter worth $292,000. Crown Advisors Management Inc. bought a new stake in shares of CervoMed in the 1st quarter worth about $2,330,000. Ikarian Capital LLC purchased a new stake in shares of CervoMed during the 1st quarter valued at about $5,530,000. Finally, RA Capital Management L.P. bought a new position in shares of CervoMed in the 1st quarter valued at about $20,075,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.
CervoMed Company Profile
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
See Also
- Five stocks we like better than CervoMed
- What is a Dividend King?
- Survey: Top 175 Fittest Retirement Locations in America
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Which Wall Street Analysts are the Most Accurate?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.